TMEM16 - Sophion

TMEM16A

(Transmembrane protein 16A, ANO1, CaCC)

 

TMEM16A (ANO1) is a calcium-activated chloride channel (CaCC) that is involved in a plethora of physiological and pathophysiological conditions. The channel is suggested as target for the treatment of asthma, secretory diarrhoeas, and hypertension, as well as an alternative to CFTR for treatment of Cystic Fibrosis. TMEM16A is unique as its gating synergistically depends on voltage and cytosolic Ca2+ (Scudieri et al. 2012).

Posters

  • View TMEM16A on Qube 384
    Year: 2017 First author: J McGivern

Papers

  • View TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis
    Year: 2020 First author: Danahay et Al.
  • View Development of a QPatch-Automated Electrophysiology Assay for Identifying TMEM16A Small-Molecule Inhibitors
    Year: 2020 First author: Henckels et Al.

Reports

  • View TMEM16A on Qube
    Year: 2017 First author: Sauter, D
Contact

This page is not optimized for smartphones and tablets.

Please visit on a larger screen.

Contact Sophion

Sophion Bioscience A/S
Baltorpvej 154, 2750 Ballerup, Denmark
Telephone: +45 44 60 88 00

You need to fill in all required fields.

When opting-in for our newsletter you will receive 4-6 newsletters per year. You can always opt-out directly from the newsletters. For more information see our privacy policy